Search research articles
Contact Us
Filters
Showing results (391-400 of 408) with videos related to
Page
of 41
Sort By:
Scientific Reports
|
May 16, 2020
Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, et al.
Biological Reviews of the Cambridge Philosophical Society
|
March 11, 2020
The ecological importance of crocodylians: towards evidence-based justification for their conservation
Ruchira Somaweera, James Nifong, Adam Rosenblatt, et al.
Clinical Pharmacology and Therapeutics
|
December 24, 2019
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection
Wei Gao, Andrea L Webber, Jill Maxwell, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
November 10, 2000
An objective analysis of process errors in trauma resuscitations
J R Clarke, B Spejewski, A S Gertner, et al.
Cancer Medicine
|
February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122
Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Journal of Neurogenetics
|
November 19, 2011
Pharmacological validation of candidate causal sleep genes identified in an N2 cross
Joseph I Brunner, Anthony L Gotter, Joshua Millstein, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Nature Medicine
|
January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial
Reinhard Dummer, Caroline Robert, Richard A Scolyer, et al.
Cancer Medicine
|
December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G Pfister, Robert I Haddad, Francis P Worden, et al.
Science (New York, N.Y.)
|
October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu, Robin Mogg, Mark Ayers, et al.
Page
of 41
Search research articles
Search
Showing results (391-400 of 408) with videos related to
Sort By:
Page
of 41
Scientific Reports
|
May 16, 2020
Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Sophie Cazanave, Alexei Podtelezhnikov, Kristian Jensen, et al.
Biological Reviews of the Cambridge Philosophical Society
|
March 11, 2020
The ecological importance of crocodylians: towards evidence-based justification for their conservation
Ruchira Somaweera, James Nifong, Adam Rosenblatt, et al.
Clinical Pharmacology and Therapeutics
|
December 24, 2019
Fine-Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection
Wei Gao, Andrea L Webber, Jill Maxwell, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine
|
November 10, 2000
An objective analysis of process errors in trauma resuscitations
J R Clarke, B Spejewski, A S Gertner, et al.
Cancer Medicine
|
February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122
Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Journal of Neurogenetics
|
November 19, 2011
Pharmacological validation of candidate causal sleep genes identified in an N2 cross
Joseph I Brunner, Anthony L Gotter, Joshua Millstein, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Nature Medicine
|
January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial
Reinhard Dummer, Caroline Robert, Richard A Scolyer, et al.
Cancer Medicine
|
December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G Pfister, Robert I Haddad, Francis P Worden, et al.
Science (New York, N.Y.)
|
October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu, Robin Mogg, Mark Ayers, et al.
Page
of 41